Medical - Healthcare Information Services
Compare Stocks
5 / 10Stock Comparison
TDOC vs UNH vs CVS vs AMWL vs CI
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Healthcare Information Services
Medical - Healthcare Plans
TDOC vs UNH vs CVS vs AMWL vs CI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Healthcare Information Services | Medical - Healthcare Plans |
| Market Cap | $1.26B | $335.60B | $111.40B | $129M | $74.85B |
| Revenue (TTM) | $2.51B | $449.71B | $407.90B | $182M | $277.94B |
| Net Income (TTM) | $-171M | $12.04B | $2.93B | $-88M | $6.29B |
| Gross Margin | 65.6% | 18.8% | 13.9% | 38.7% | 9.3% |
| Operating Margin | -7.6% | 4.2% | 1.5% | -50.6% | 3.4% |
| Forward P/E | — | 20.2x | 12.2x | — | 9.4x |
| Total Debt | $1.04B | $78.39B | $93.59B | $5M | $31.46B |
| Cash & Equiv. | $781M | $24.36B | $8.51B | $182M | $7.68B |
TDOC vs UNH vs CVS vs AMWL vs CI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 20 | May 26 | Return |
|---|---|---|---|
| Teladoc Health, Inc. (TDOC) | 100 | 3.2 | -96.8% |
| UnitedHealth Group … (UNH) | 100 | 118.6 | +18.6% |
| CVS Health Corporat… (CVS) | 100 | 149.5 | +49.5% |
| American Well Corpo… (AMWL) | 100 | 1.3 | -98.7% |
| Cigna Corporation (CI) | 100 | 167.6 | +67.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TDOC vs UNH vs CVS vs AMWL vs CI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
TDOC lags the leaders in this set but could rank higher in a more targeted comparison.
UNH is the #2 pick in this set and the best alternative if growth and quality is your priority.
- 11.8% revenue growth vs AMWL's -2.0%
- 2.7% margin vs AMWL's -48.2%
CVS carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 0 yrs, beta 0.05, yield 3.1%
- Beta 0.05, yield 3.1%, current ratio 0.84x
- Beta 0.05 vs TDOC's 1.91
- 3.1% yield, vs UNH's 2.4%, (2 stocks pay no dividend)
AMWL is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.47, Low D/E 1.8%, current ratio 3.37x
CI ranks third and is worth considering specifically for growth exposure and long-term compounding.
- Rev growth 11.3%, EPS growth 82.9%, 3Y rev CAGR 15.1%
- 136.5% 10Y total return vs UNH's 220.6%
- Better valuation composite
- 4.1% ROA vs AMWL's -25.1%, ROIC 10.4% vs -95.1%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 11.8% revenue growth vs AMWL's -2.0% | |
| Value | Better valuation composite | |
| Quality / Margins | 2.7% margin vs AMWL's -48.2% | |
| Stability / Safety | Beta 0.05 vs TDOC's 1.91 | |
| Dividends | 3.1% yield, vs UNH's 2.4%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +34.7% vs CI's -13.3% | |
| Efficiency (ROA) | 4.1% ROA vs AMWL's -25.1%, ROIC 10.4% vs -95.1% |
TDOC vs UNH vs CVS vs AMWL vs CI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
TDOC vs UNH vs CVS vs AMWL vs CI — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
CI leads in 2 of 6 categories
CVS leads 2 • TDOC leads 0 • UNH leads 0 • AMWL leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — TDOC and UNH and CVS each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UNH is the larger business by revenue, generating $449.7B annually — 2464.3x AMWL's $182M. UNH is the more profitable business, keeping 2.7% of every revenue dollar as net income compared to AMWL's -48.2%. On growth, CVS holds the edge at +6.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2.5B | $449.7B | $407.9B | $182M | $277.9B |
| EBITDAEarnings before interest/tax | $42M | $23.2B | $10.5B | -$59M | $12.1B |
| Net IncomeAfter-tax profit | -$171M | $12.0B | $2.9B | -$88M | $6.3B |
| Free Cash FlowCash after capex | $251M | $19.7B | $7.4B | -$42M | $7.7B |
| Gross MarginGross profit ÷ Revenue | +65.6% | +18.8% | +13.9% | +38.7% | +9.3% |
| Operating MarginEBIT ÷ Revenue | -7.6% | +4.2% | +1.5% | -50.6% | +3.4% |
| Net MarginNet income ÷ Revenue | -6.8% | +2.7% | +0.7% | -48.2% | +2.3% |
| FCF MarginFCF ÷ Revenue | +10.0% | +4.4% | +1.8% | -22.9% | +2.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -2.5% | +2.0% | +6.2% | -100.0% | +4.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +32.1% | +0.7% | +63.1% | +44.5% | +29.1% |
Valuation Metrics
CI leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 12.8x trailing earnings, CI trades at a 80% valuation discount to CVS's 62.8x P/E. On an enterprise value basis, CI's 8.4x EV/EBITDA is more attractive than UNH's 16.7x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.3B | $335.6B | $111.4B | $129M | $74.9B |
| Enterprise ValueMkt cap + debt − cash | $1.5B | $389.6B | $196.5B | -$48M | $98.6B |
| Trailing P/EPrice ÷ TTM EPS | -6.11x | 27.95x | 62.81x | -1.30x | 12.81x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 20.19x | 12.19x | — | 9.36x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 15.13x | 16.70x | 13.11x | — | 8.39x |
| Price / SalesMarket cap ÷ Revenue | 0.50x | 0.75x | 0.28x | 0.52x | 0.27x |
| Price / BookPrice ÷ Book value/share | 0.89x | 3.31x | 1.47x | 0.50x | 1.80x |
| Price / FCFMarket cap ÷ FCF | 4.40x | 20.88x | 14.27x | — | 8.92x |
Profitability & Efficiency
CI leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
CI delivers a 15.1% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-33 for AMWL. AMWL carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to CVS's 1.24x. On the Piotroski fundamental quality scale (0–9), CI scores 8/9 vs CVS's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -12.4% | +11.5% | +3.9% | -33.5% | +15.1% |
| ROA (TTM)Return on assets | -5.9% | +3.9% | +1.1% | -25.1% | +4.1% |
| ROICReturn on invested capital | -11.5% | +9.2% | +5.0% | -95.1% | +10.4% |
| ROCEReturn on capital employed | -10.0% | +9.7% | +6.1% | -36.6% | +9.2% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 | 5 | 6 | 8 |
| Debt / EquityFinancial leverage | 0.75x | 0.77x | 1.24x | 0.02x | 0.75x |
| Net DebtTotal debt minus cash | $259M | $54.0B | $85.1B | -$178M | $23.8B |
| Cash & Equiv.Liquid assets | $781M | $24.4B | $8.5B | $182M | $7.7B |
| Total DebtShort + long-term debt | $1.0B | $78.4B | $93.6B | $5M | $31.5B |
| Interest CoverageEBIT ÷ Interest expense | -8.76x | 4.71x | 2.11x | -239.18x | 6.77x |
Total Returns (Dividends Reinvested)
CVS leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CI five years ago would be worth $11,850 today (with dividends reinvested), compared to $278 for AMWL. Over the past 12 months, CVS leads with a +34.7% total return vs CI's -13.3%. The 3-year compound annual growth rate (CAGR) favors CVS at 11.0% vs AMWL's -42.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -1.3% | +10.6% | +10.6% | +59.8% | +2.3% |
| 1-Year ReturnPast 12 months | +1.5% | -3.2% | +34.7% | +14.3% | -13.3% |
| 3-Year ReturnCumulative with dividends | -73.3% | -19.9% | +36.6% | -80.7% | +13.6% |
| 5-Year ReturnCumulative with dividends | -95.4% | -2.6% | +17.0% | -97.2% | +18.5% |
| 10-Year ReturnCumulative with dividends | -41.1% | +220.6% | +3.5% | -98.3% | +136.5% |
| CAGR (3Y)Annualised 3-year return | -35.6% | -7.1% | +11.0% | -42.2% | +4.4% |
Risk & Volatility
CVS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CVS is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than TDOC's 1.91 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.5% from its 52-week high vs TDOC's 71.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.91x | 0.59x | 0.05x | 1.47x | 0.35x |
| 52-Week HighHighest price in past year | $9.77 | $395.52 | $88.63 | $9.15 | $338.89 |
| 52-Week LowLowest price in past year | $4.40 | $234.60 | $58.35 | $3.71 | $239.51 |
| % of 52W HighCurrent price vs 52-week peak | +71.2% | +93.5% | +98.5% | +84.7% | +83.8% |
| RSI (14)Momentum oscillator 0–100 | 74.1 | 75.9 | 69.3 | 67.1 | 53.5 |
| Avg Volume (50D)Average daily shares traded | 5.5M | 7.9M | 7.4M | 59K | 1.5M |
Analyst Outlook
Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: TDOC as "Hold", UNH as "Buy", CVS as "Buy", CI as "Buy". Consensus price targets imply 15.5% upside for CI (target: $328) vs 4.2% for UNH (target: $385). For income investors, CVS offers the higher dividend yield at 3.06% vs CI's 2.13%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | — | Buy |
| Price TargetConsensus 12-month target | $7.58 | $385.43 | $95.20 | — | $328.00 |
| # AnalystsCovering analysts | 42 | 52 | 41 | — | 39 |
| Dividend YieldAnnual dividend ÷ price | — | +2.4% | +3.1% | — | +2.1% |
| Dividend StreakConsecutive years of raises | — | 25 | 0 | — | 6 |
| Dividend / ShareAnnual DPS | — | $8.70 | $2.67 | — | $6.06 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +1.7% | 0.0% | +0.0% | +4.8% |
CI leads in 2 of 6 categories (Valuation Metrics, Profitability & Efficiency). CVS leads in 2 (Total Returns, Risk & Volatility). 2 tied.
TDOC vs UNH vs CVS vs AMWL vs CI: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is TDOC or UNH or CVS or AMWL or CI a better buy right now?
For growth investors, UnitedHealth Group Incorporated (UNH) is the stronger pick with 11.
8% revenue growth year-over-year, versus -2. 0% for American Well Corporation (AMWL). Cigna Corporation (CI) offers the better valuation at 12. 8x trailing P/E (9. 4x forward), making it the more compelling value choice. Analysts rate UnitedHealth Group Incorporated (UNH) a "Buy" — based on 52 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — TDOC or UNH or CVS or AMWL or CI?
On trailing P/E, Cigna Corporation (CI) is the cheapest at 12.
8x versus CVS Health Corporation at 62. 8x. On forward P/E, Cigna Corporation is actually cheaper at 9. 4x.
03Which is the better long-term investment — TDOC or UNH or CVS or AMWL or CI?
Over the past 5 years, Cigna Corporation (CI) delivered a total return of +18.
5%, compared to -97. 2% for American Well Corporation (AMWL). Over 10 years, the gap is even starker: UNH returned +220. 6% versus AMWL's -98. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — TDOC or UNH or CVS or AMWL or CI?
By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.
05β versus Teladoc Health, Inc. 's 1. 91β — meaning TDOC is approximately 3679% more volatile than CVS relative to the S&P 500. On balance sheet safety, American Well Corporation (AMWL) carries a lower debt/equity ratio of 2% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — TDOC or UNH or CVS or AMWL or CI?
By revenue growth (latest reported year), UnitedHealth Group Incorporated (UNH) is pulling ahead at 11.
8% versus -2. 0% for American Well Corporation (AMWL). On earnings-per-share growth, the picture is similar: Cigna Corporation grew EPS 82. 9% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, CI leads at 15. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — TDOC or UNH or CVS or AMWL or CI?
UnitedHealth Group Incorporated (UNH) is the more profitable company, earning 2.
7% net margin versus -38. 4% for American Well Corporation — meaning it keeps 2. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UNH leads at 4. 2% versus -42. 2% for AMWL. At the gross margin level — before operating expenses — TDOC leads at 69. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is TDOC or UNH or CVS or AMWL or CI more undervalued right now?
On forward earnings alone, Cigna Corporation (CI) trades at 9.
4x forward P/E versus 20. 2x for UnitedHealth Group Incorporated — 10. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CI: 15. 5% to $328. 00.
08Which pays a better dividend — TDOC or UNH or CVS or AMWL or CI?
In this comparison, CVS (3.
1% yield), UNH (2. 4% yield), CI (2. 1% yield) pay a dividend. TDOC, AMWL do not pay a meaningful dividend and should not be held primarily for income.
09Is TDOC or UNH or CVS or AMWL or CI better for a retirement portfolio?
For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
05), 3. 1% yield). Teladoc Health, Inc. (TDOC) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CVS: +3. 5%, TDOC: -41. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between TDOC and UNH and CVS and AMWL and CI?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: TDOC is a small-cap quality compounder stock; UNH is a large-cap quality compounder stock; CVS is a mid-cap income-oriented stock; AMWL is a small-cap quality compounder stock; CI is a mid-cap deep-value stock. UNH, CVS, CI pay a dividend while TDOC, AMWL do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.